Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Fecal occult blood tests make cost effective alternatives in colorectal cancer screening

While colonoscopies are the most accurate method for the early detection of colorectal cancers, screening with fecal occult blood tests results in more efficient use of limited budgets, according to a new study by researchers at RTI International.

30 Jul 2010

Exact Sciences to demonstrate methylation specific technology at AACC annual meeting

Exact Sciences Corp. today announced that data being presented this afternoon at the annual meeting of the American Association of Clinical Chemistry demonstrates that its methylation specific technology, using a combination of DNA methylation markers, detected 100 percent of colorectal cancers and precancers at a specificity cutoff of 100 percent in a preliminary study with colorectal tissue.

29 Jul 2010

Etubics enters Phase I trials for next generation vector vaccines

Etubics Corporation, a biopharmaceutical company developing next generation vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S. Food and Drug Administration for its Investigational New Drug application to begin studying ETBX-011 in humans.

29 Jul 2010

Exact Sciences reports total revenues of $1.3M for second-quarter 2010

Exact Sciences Corp. today announced its financial results for the second quarter ended June 30, 2010.

28 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

National health campaigns make men less likely to choose cancer screening: Study

In Germany, several national health campaigns promote cancer screening by announcing that only one in five German men gets screened. This is supposed to motivate men to have an examination. But a new study published in Psychological Science, a journal of the Association for Psychological Science, finds that this well-meaning message has the exact opposite effect: it makes men less likely to choose to get screened.

28 Jul 2010

Axela acquires Xceed Molecular

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.

26 Jul 2010

Research roundup: Hospital emergency room HIV screenings; Medical device reviews; Health law impact on docs and hospitals

Physician Satisfaction With Chronic Care Processes: A Cluster-Randomized Trial Of Guided Care - The authors randomly assigned teams of physicians and their chronically ill older patients into groups that either provided Guided Care - an educated registered nurse works with a primary care practice team to enhance quality of care - or usual care. One year later, they measured "physicians' satisfaction with chronic care processes, time spent on chronic care, knowledge of their chronically ill older patients, and care coordination provided by physicians and office staff."

26 Jul 2010

Lack of insurance coverage and fees deter willingness to undergo CTC for colorectal cancer screening

A recent questionnaire submitted to a group of patients at one of the nation's largest general hospitals suggests that a significant number of patients, who have previously refused colorectal cancer screening, are willing to undergo computed tomography colonography (CTC) (or virtual colonoscopy), but not willing to pay for the exam themselves when not covered by insurance, according to a study in the August issue of the American Journal of Roentgenology (www.ajronline.org).

22 Jul 2010

Affymetrix second-quarter total revenue decreases to $71.7 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.

22 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Rate of women getting mammography screenings stalls; colorectal cancer screenings remain underused by medicare patients

One-fifth of American women ages 50 to 74 have fallen behind on mammography screenings for breast cancer, the Centers for Disease Control and Prevention are reporting. Although the percentage of women in this age group who get a regular breast cancer screening every two years increased steadily during the 1990s, the rate has remained just over 80 percent since 2000, according to the centers' Morbidity and Mortality Weekly Report.

21 Jul 2010

ARUP announces new version of Septin 9 methylated DNA test

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced it is offering the Septin 9 methylated DNA test, a new blood-based colorectal cancer screening method. While ARUP is not the first laboratory to offer this test, this new version, developed and validated independently by ARUP, is clinically proven to detect a higher proportion of colorectal cancers than Septin 9 tests developed by other companies.

20 Jul 2010

Combined technologies offer promise for detecting colon cancer in women

A team led by a Northwestern University biomedical engineer has found that combining novel optical technologies with a common colon cancer screening test may allow doctors to more accurately detect the presence of colon cancer, particularly in women.

20 Jul 2010

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed.

17 Jul 2010

NEOP receives stockholder approval to increase company shares to 205 milliion

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.

17 Jul 2010

An overview of AAPM annual meeting

AAPM is the premier organization in medical physics, a broadly-based scientific and professional discipline encompassing physics principles and applications in medicine and biology. Its membership includes medical physicists who specialize in research that develops cutting-edge technologies and board-certified clinical medical physicists who apply these technologies in community hospitals, clinics, and academic medical centers.

16 Jul 2010

Survival rates of nine types of cancer in Spain

Spanish epidemiologists have presented information on survival of nine types of cancer in Spain and have compared it with other European countries. At five years from diagnosis, the lowest survival rate is observed in lung cancer (less than 11%), and the highest in testicular cancer (95%). Cancer survival in Spain is at the European average.

16 Jul 2010

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

Keryx Biopharmaceuticals, Inc. today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of neuroblastoma, a cancer of the nervous system affecting mostly children and infants for which there are no FDA approved therapies.

15 Jul 2010

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.

15 Jul 2010

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Fecal occult blood tests make cost effective alternatives in colorectal cancer screening

Exact Sciences to demonstrate methylation specific technology at AACC annual meeting

Etubics enters Phase I trials for next generation vector vaccines

Exact Sciences reports total revenues of $1.3M for second-quarter 2010

Regeneron second-quarter total revenues increase to $115.9 million

National health campaigns make men less likely to choose cancer screening: Study

Axela acquires Xceed Molecular

Research roundup: Hospital emergency room HIV screenings; Medical device reviews; Health law impact on docs and hospitals

Lack of insurance coverage and fees deter willingness to undergo CTC for colorectal cancer screening

Affymetrix second-quarter total revenue decreases to $71.7 million

Researchers find that increase in leptin may promote colorectal neoplasms

Rate of women getting mammography screenings stalls; colorectal cancer screenings remain underused by medicare patients

ARUP announces new version of Septin 9 methylated DNA test

Combined technologies offer promise for detecting colon cancer in women

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

NEOP receives stockholder approval to increase company shares to 205 milliion

An overview of AAPM annual meeting

Survival rates of nine types of cancer in Spain

KRX-0401 receives Orphan Drug designation from FDA for treatment of neuroblastoma

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in